164 results about "Oral solutions" patented technology

The invention discloses a CAD detection method for phosphoric acid and phosphorous acid in an alendronate sodium oral solution, and belongs to the technical field of pharmaceutical analysis. The method comprises the following steps: preparing a reference stock solution and a test solution; then setting high performance liquid chromatography detection conditions; a Shodex VN-504D chromatographic column is adopted, a CAD detector is adopted as a detector, a mixed solution of a mobile phase A and a mobile phase B is adopted as a mobile phase, the mobile phase A is ammonium formate, the mobile phase B is an acetonitrile solution, and gradient elution is performed by adopting the mobile phase; and respectively measuring the reference stock solution and the test solution, injecting into a liquid chromatograph, and recording a chromatogram. A CAD detector is adopted, the detection sensitivity is obviously improved, the quantitative concentration can reach 0.24 mu g / mL, and the detection concentration can reach 0.10 mu g / mL. The method is high in specificity, high in sensitivity, good in durability, rapid, simple, effective and reliable.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

Disclosed herein is a ready-to-use, non-aqueous oral solution of losartan. Also disclosed herein is a method of preparing a ready-to-use, non-aqueous oral solution of losartan and its method of use.

The invention relates to a method for determining the content of sorbitol and glycerol as auxiliary materials in a fudosteine oral solution, which has the advantages of high sensitivity, strong specificity, good accuracy and simple and rapid operation, can reduce the difficulty of preparation development, reduce the workload of prescription development, shorten the research and development time and further improve the BE passing rate, and has practical significance.

The application belongs to the technical field of drug dissolution and dispersion, and particularly relates to a bunazosin water-based solution preparation and a preparation method. The bunazosin water-based solution preparation provided by the application comprises the following components: bunazosin, gamma-cyclodextrin, lecithin, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, aspartame and water. The above components are mixed to be homogeneous to prepare an oral solution which is uniform, clear and can be stored for a long time. The scheme of the application further enriches the dosage form of bunazosin, improves the convenience of taking bunazosin, and is expected to help improve the oral bioavailability and absorption efficiency of bunazosin. The scheme of the application also provides a reference direction for the mechanism research on the dissolution and dispersion behavior of the insoluble bunazosin macromolecule in a water medium.

The present application provides a detection method and quality control method for related substances in dextromethorphan oral solution, which comprises the following steps: dissolving dextromethorphan oral solution in a solvent to obtain a test solution; and performing high performance liquid chromatography detection on the test solution; the mobile phase used in the high performance liquid chromatography detection comprises mobile phase A and mobile phase B, the mobile phase A comprises a phosphate solution, the mobile phase B comprises acetonitrile, and the concentration of the phosphate solution is 0.1 mM-10 mM. The detection method has good linear relationship between dextromethorphan and related substances, good accuracy and sensitivity, strong specificity, high stability, good separation degree and good reproducibility, and is suitable for wide application.

The invention relates to the technical field of medicines, in particular to a briracetam oral solution and a preparation method thereof. According to the present invention, by adjusting the formula and the preparation process of the oral solution of the briracetam, the stability of the briracetam is effectively improved, the antibacterial effect is effectively improved without adding the preservative, the taste of the oral solution is adjusted, and the medication compatibility of children patients is improved.

1. Name of the designed product: packing box (milk fruit sugar oral solution). 2. Use of the designed product: for product packing. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo showing the design points: perspective view 1.

The invention discloses a data security traceability system and method in an oral solution medicine production process, and belongs to the technical field of medicine data security traceability. The system comprises a data traceability module which constructs an information data traceability chain based on each group of factory oral solution drugs; the source data calling module is used for calling the information data traceability chain of the oral solution medicine with the query information and marking source data; the risk analysis module is used for determining risk data of the oral solution medicine on the basis of a plurality of pieces of source data and the number of the marked query information corresponding to each piece of source data; the medicine distribution area management module is used for determining the number of oral solution medicines with risk data in each area based on the transportation data of the medicine distribution area; and the safety early warning module is used for judging whether a disease spreading risk exists or not based on the sales data of the medicine distribution area. According to the invention, abnormal data in the drug production and circulation process can be accurately locked through the traceability system, and the transparency of drug information is improved.

The present application relates to the field of pharmaceutical analysis, and particularly relates to a method for determining the content of cetirizine hydrochloride and preservatives in cetirizine hydrochloride oral solution. The method provided by the present application uses octadecyl bonded silica as the filler of the chromatographic column, uses a mixed solution with specific composition and proportion as the mobile phase, adopts isocratic elution, uses a content volumetric pipette to prepare the test sample solution, injects the test sample solution and the mixed control solution into the liquid chromatograph respectively to perform liquid chromatography, thereby obtaining the chromatogram of the test sample solution and the chromatogram of the mixed control solution respectively; and then according to the external standard method, the content of cetirizine hydrochloride, the content of the hydroxy methylbenzoate preservative and the content of the hydroxy propylbenzoate preservative in the cetirizine hydrochloride oral solution are calculated by the peak area. The method has strong specificity, high accuracy, good precision, linear relationship and stability, and is conducive to the evaluation of sample quality.

1. Name of the designed product: medicine packing box (vitamin D oral solution). 2. Use of the designed product: packing for vitamin D oral solution. 3. Design points of the designed product: in the pattern. 4. Picture or photo best indicating the design points: perspective view.

Liquid formulation including cevimeline hydrochloride and a combination of at least one sweetener and at least one flavoring agent to mask the bitter taste of cevimeline hydrochloride oral solutions. The liquid formulation may be administered to a patient to alleviate dry mouth symptoms associated with xerostomia and Sjogren's syndrome.

The utility model discloses a kind of oral liquid bottle caps with quantitative drop hole, comprising: inner plug, insert in oral liquid bottle mouth;And outer cover, cover on oral liquid bottle mouth, and cover inner plug in it;The inner plug includes plug body;Dripping channel is provided in the middle part of the plug body, and dripping port is provided at the top of the plug body, and liquid inlet is provided at the bottom of the plug body, dripping port and dripping channel intercommunicate, and dripping channel and liquid inlet intercommunicate;Extension body structure is provided at the side of the plug body, airflow passage I that passes through up and down is provided in the extension body structure, airflow passage II that passes through up and down is provided in plug body, and airflow passage I is communicated with airflow passage II.The utility model does not need external suction tube or dropper, with quantitative dripping function, solve most oral solution in the course of taking cannot control medicine liquid drop speed and drop weight, cannot realize the problem of accurate quantitative dosing.

The present invention relates to a novel oral solution of a bitter drug using vitamin E TPGS as a masking agent. Atoxetine HCl is an example of a bitter drug, the bitter taste of which can be masked by the presence of vitamin E TPGS.

1. The name of the design product: packaging box (atomoxetine hydrochloride oral solution). 2. The use of the design product: the design is used for packaging atomoxetine hydrochloride oral solution. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view.

1. Name of the product in this design: Packaging Box (Danfang Sodium Phosphate Oral Solution). 2. Purpose of this design: For product packaging. 3. The key design features of this product are the combination of pattern and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

This utility model discloses a mixing tank for producing lactulose oral solution. Its structure includes a main body, an upper conveying cylinder, and a lower conveying cylinder. Raw materials are conveyed through the inlet to the upper conveying cylinders on both sides, causing the materials inside to move simultaneously towards the central connection port. The materials on both sides push against each other, resulting in the first stage of fusion. Then, under the influence of a lower spiral auger inside the lower conveying cylinder, the materials separate and move to both sides, thus performing a second stage of mixing. Subsequently, the materials are fed into the lower end of the main body through the discharge port. A third motor drives a rotating shaft, causing a stirring rod to agitate the materials again, resulting in further mixing. Then, at the lowest point, a fourth motor drives a rotating shaft, causing the stirring rod to rotate, thus mixing the materials again, resulting in higher mixing efficiency and better mixing effect.

This invention provides a sample pretreatment method and identification method for identifying ginseng polysaccharides in compound fluorouracil oral solution, belonging to the field of pharmaceutical detection and analysis technology. The sample pretreatment method of this invention includes: centrifuging the compound fluorouracil oral solution and taking the clear solution; adding silica gel to the clear solution, mixing, and removing the solvent to obtain a solid mixture; adding ethanol solution or anhydrous ethanol to the obtained solid mixture, heating and refluxing, discarding the ethanol solution, and obtaining the residue; adding water to the obtained residue, sequentially extracting and centrifuging, taking the supernatant obtained by centrifugation, removing the solvent from the supernatant, and then redissolving it with water; the identification method of this invention is thin-layer chromatography analysis, and the developing solvent includes the following components in parts by volume: 6.8-9.2 parts of n-propanol, 1.76-2.24 parts of water, 0.75-1.24 parts of ethyl acetate, and 0.75-1.24 parts of glacial acetic acid. The sample pretreatment method and identification method for identifying ginseng polysaccharides in compound fluorouracil oral solution of this invention have high specificity.

The utility model discloses a stock solution filtering device for preparing a calcium zinc gluconate oral solution, which comprises a stock solution storage tank and a filtering tank, the outer surface of the stock solution storage tank is fixedly communicated with an eduction pipe, the outer surface of the filtering tank is fixedly communicated with an ingress pipe, and a multi-layer processing mechanism is arranged between the eduction pipe and the ingress pipe. The multi-layer treatment mechanism is used for carrying out pre-filtration treatment on the stock solution and extracting impurities or particles in the stock solution after pre-filtration, and relates to the technical field of stock solution filtration for preparing the calcium and zinc gluconate oral solution. Furthermore, the collecting box with impurities is extracted from the interior of the treatment box, and the collecting box without impurities is put into the treatment box, so that the conveying of the stock solution does not need to be stopped when the collecting boxes are replaced, and the filtering efficiency of the stock solution is ensured.

This invention provides an birepiperazole oral solution, wherein the solution comprises birepiperazole 0.4-0.6 mg / ml, disodium edetate 0.1-0.5 mg / ml, methylparaben 1.5-2.0 mg / ml, propylparaben 0.15-0.25 mg / ml, an acidic pH adjuster 2.5-3.5 mg / ml, a flavoring agent 0.8-1.2 mg / ml, propylene glycol 40-60 mg / ml, glycerin 120-180 mg / ml, and a sodium hydroxide solution to adjust the pH to 2.9-3.3. The drug exhibits high stability during preparation, storage, and clinical formulation.

The application discloses a stable isoniazid oral solution, which comprises isoniazid, hydroxybenzyl methyl ester, hydroxybenzyl propyl ester, a pH regulator and a solvent. The application prepares the isoniazid oral solution with good stability, improves the absorption and utilization rate of the medicament, and has good taste and market prospect.

The invention discloses a low-disubstituted impurity ciprofloxacin hydrochloride liquid pharmaceutical preparation and a preparation method thereof, and belongs to the field of pharmacy. Aiming at the problem that the light stability and the damp-heat stability of the existing ciprofloxacin hydrochloride solution preparation are difficult to improve synchronously, the preparation disclosed by the invention is composed of ciprofloxacin hydrochloride, tryptophan, weakly acidic buffer pair salt, a solvent and pharmaceutically acceptable auxiliary materials, and the pH value of the preparation is 5.5-7.0. According to the invention, tryptophan is added and the pH is cooperatively regulated, so that the light stability and the damp-heat stability of the preparation are remarkably improved, and the preparation process is simple, convenient and controllable, can be adapted to various liquid dosage forms such as injections, eye drops and oral solutions, and has a good industrial conversion prospect.

The invention relates to an anti-inflammatory and bacteriostatic oral liquid containing lactic acid bacteria and a preparation method, and belongs to the technical field of oral care, the oral liquid comprises the following raw materials: lactic acid bacteria freeze-dried powder, a plant extract, plant essential oil, a humectant, a flavoring agent, a solubilizer, an antioxidant and deionized water. The lactobacillus paracasei, the pediococcus pentosaceus and the leuconostoc mesenteroides are used as compound lactobacillus freeze-dried powder, adhesion of pathogenic bacteria in an oral cavity and formation of a pathogenic bacteria biological membrane can be effectively inhibited, combination of pathogenic microorganisms and tooth surfaces can be interfered through an immunoregulation mechanism, and therefore the oral liquid is endowed with an excellent bacteriostatic effect; the bletilla striata extract, the clausena lansium extract, the curcuma zedoary extract and the liquorice extract are selected as plant extracts, so that the prepared oral liquid has a prominent anti-inflammatory effect from different aspects of repair promotion, anti-inflammation and bacteriostasis; meanwhile, by compounding the myrtle wood oil, the fructus amomi oil and the sage oil, the oral liquid can also be endowed with a remarkable deodorization effect.

The invention discloses a production process of an ambroxol oral solution, and belongs to the technical field of chemical medicinal preparations, the production process comprises the following steps: adding an aqueous solution containing ambroxol hydrochloride, clenbuterol hydrochloride, sorbitol, propylene glycol, glycerol, hydroxyethyl cellulose, DL-tartaric acid and sodium benzoate into a reaction kettle, and uniformly stirring to obtain the ambroxol hydrochloride oral solution, the clenbuterol hydrochloride, the sorbitol, the propylene glycol, the glycerol, the hydroxyethyl cellulose, the DL-tartaric acid and the sodium benzoate; the preparation method comprises the following steps: preparing in a production system passivated by hydroxyethyl diamine tetraacetic acid trisodium salt, treating by a two-stage series hollow membrane contactor, and finally filling a glass bottle with a liquid medicine. According to the preparation method disclosed by the invention, on the basis of prescription adjustment without adding antioxidants such as sodium pyrosulfite and the like, the impurities of the medicine in the production and storage processes are obviously reduced, the product stability and the clinical medication safety are improved, and the preparation process is simple and stable to operate and suitable for industrial production.

The invention belongs to the field of biological medicine, and particularly discloses an acute intestinal injury targeted therapy drug based on an MAIT cell viability evaluation algorithm and application thereof. The MAIT cell activity parameters (including CD3 + TCR beta + MR1 + cell proportion and IL-17A secretion volume) in a patient sample are detected through flow cytometry, quantification is carried out according to an algorithm activity score = (MR1 + cell proportion * 0.4) + (IL-17A concentration / 50 * 0.6), and the patient with the score larger than or equal to 2.0 is suitable for targeted therapy. An oral solution (with the concentration of 5-20 [mu] M) taking acetyl-6-formyl pterin (Ac-6FP) as a core is adopted for treatment, intestinal injury is relieved by specifically inhibiting the IL-17A secretion function of MAIT cells, the intestinal barrier function is remarkably improved in an animal model, and the survival rate is increased. Meanwhile, the matched kit integrates the antibody detection assembly and the Ac-6FP medicine, and diagnosis and treatment integration is achieved. The invention provides a precise targeted treatment strategy and medicine for acute intestinal injury.

The invention discloses an oral solution for treating xerophthalmia and a preparation method thereof, and belongs to the technical field of biological pharmacy. The oral solution for treating the xerophthalmia is prepared from the following components in parts by weight: 15 to 18 parts of fructus lycii extract, 15 parts of bilberry extract, 10 to 11 parts of taurine, 2.4 to 2.6 parts of zinc gluconate, 750 to 760 parts of grape concentrated juice and the balance of water, the content of soluble solids in the grape concentrated juice is 64 to 66-degree Brix, and the content of total acids is 1.75 to 2.32 percent. In the storage process of the oral solution, the anthocyanin has good stability.

The invention relates to a non-aqueous oral solution comprising: losartan potassium in an amount of 0.01 mg / mL to 50 mg / mL, such as 10 mg / mL; a solubiliser, such as polyethylene glycol 400 in an amoun

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.